Figure 6.
Post-M. tuberculosis protective efficacy of CysVac2 delivery. C57BL/6 mice (n=5) were infected with ~100 CFU of M. tuberculosis by aerosol route and 4 weeks later were vaccinated with BCG or three times s.c. with 3 μg CysVac2 formulated in MPL/DDA. Eight weeks after the last vaccination the frequency of CysVac2-specific CD4+ T cells producing IFN-γ, IL-2 or TNF (a) or Il-17 (b) was determined in lung cells stimulated ex vivo with CysVac2 in the presence of brefeldin A. M. tuberculosis CFU in the lung at 8 weeks post-vaccination (c). The data are presented as Log10 of the mean of CFU±s.e.m., and are representative of three independent experiments. The significance of differences between groups was determined by one or two-way analysis of variance (ANOVA) (ns, not significant; *P<0.05; **P<0.01;). Photomicrographs of haematoxylin and eosin (H&E) stain of middle right lobes of unvaccinated mice (d) and CysVac2 vaccinated mice (e). Arrows indicate granulomas.